Shots:

• The voluntary Class I recall of Ambaro is due to presence of trace amounts of N-nitrosodiethylamine (NDEA) & N-nitrosodimethylamine (NDMA) in marketed b/w 3 Dec-2018 to 23 Jan-2019
• The recall is for no. of 763-000 tablets- manufactured in April to July 2018 which contained cancer causing substance- also examined by WHO
• Additionally- Teva and Mylan initiated their recalls in Jan-2019 and Dec-2018 respectively for valsartan lots used as anti-hypertensive medication

Click here to read full press release/ article | Ref: Pfizer | Image: Wall Street Journal